54 completed, 8 unknown, 7 recruiting, 7 terminated. 24 Not applicable, 17 Phase 1, 16 Phase 2, 9 Phase 3, 9 Phase 4.
Follow Type II Diabetes Mellitus: new trials by email Literature Review of Type II Diabetes Mellitus trials Research Report on Type II Diabetes Mellitus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| cfMSC Therapy for Diabetes cfMSC therapy for diabetes - Type II Diabetes Mellitus | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Pain Neuroscience Education and Graded Motor Imagery Combined With Conventional Physiotherapy on Diabetic Adhesive Capsulitis Pain Neuroscience Education (PNE), Graded Motor Imagery (GMI), Conventional Physiotherapy - Diabetic Adhesive Capsulitis, Frozen Shoulder | Not applicable | Not yet recruiting | Riphah International University | 50 | 2026-08-15 | 2026-08-13 |
| Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency GL0034 - Type II Diabetes Mellitus | Phase 1 | Recruiting | Sun Pharmaceutical Industries Limited | 40 | 2026-02-25 | 2026-03-13 |
| A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus CX11, Placebo - Type II Diabetes Mellitus | Phase 2 | Recruiting | Corxel Pharmaceuticals | 240 | 2026-02-06 | 2026-09-15 |
| Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus GL0034 Dose Level 1, GL0034 Dose Level 2, GL0034 Dose Level 3 - Type II Diabetes Mellitus | Phase 2 | Recruiting | Sun Pharmaceutical Industries Limited | 285 | 2026-01-20 | 2026-03-18 |
| The GRoceries Aimed at Increasing Nutrition Study Marketing Nudges Only, Marketing Nudges + Dynamically Adapted Financial Incentives - Type 2 Diabetes, Type II Diabetes Mellitus | Not applicable | Active not recruiting | University of Pennsylvania | 219 | 2025-10-14 | 2026-10-20 |
| Combination of Lactulose and Polyethylene Glycol Electrolytes Powder (PEG-ELS) for Bowel Preparation in Type II Diabetes Mellitus Patients lactulose, PEG (solution given 4 L) - Type II Diabetes Mellitus | Not applicable | Completed | General Hospital of Shenyang Military Region | 300 | 2025-09-04 | 2026-09-25 |
| Short- and Long-Term Effects of Whole-Body Photobiomodulation in Type II Diabetes Patients: A Protocol for a Controlled Clinical Trial PBM, Placebo PBM - Type II Diabetes Mellitus | Not applicable | Not yet recruiting | University of Malaga | 44 | 2025-08-30 | 2025-07-02 |
| Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors [EMPOWER-D] Participatory, Learning and Action Based Intervention - Type II Diabetes Mellitus, Intermediate Hyperglycemia (IHG) | Not applicable | Recruiting | Khyber Medical University Peshawar | 12744 | 2025-05-01 | 2025-09-02 |
| Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors PLA - Diabetes Type 2, Type II Diabetes Mellitus | Not applicable | Recruiting | HealthNet Transcultural Psychosocial Organization | 250 | 2024-12-24 | 2026-01-20 |
| A Clinical Trial to Evaluate the Food Effect of CKD-379 CKD-379 - Type II Diabetes Mellitus | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2024-11-05 | 2024-12-30 |
| Feasibility Trial in Urban Pakistan for Community Engagement in Preventing Type II Diabetes and Risk Factors Participatory, learning and Action (PLA) Based intervention - Type II Diabetes Mellitus | Not applicable | Recruiting | Baqai Institute of Diabetology and Endocrinology | 240 | 2024-06-24 | 2024-08-26 |
| A Clinical Trial to Evaluate the Food Effect of CKD-378 CKD-378, QD, PO - Type II Diabetes Mellitus | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2024-05-03 | 2024-07-08 |
| Effects of Eccentric Training on Glycemic Control and Quality of Life in Patients With Type II Diabetes Mellitus Eccentric Training - Type II Diabetes Mellitus | Not applicable | Unknown | Foundation University Islamabad | 24 | 2024-03-20 | 2024-04-29 |
| Relative Hand Grip Strength and Functional Fitness in Diabetic Patient in Egypt relative Hand grip strength, senior fitness test - Type II Diabetes Mellitus | Not applicable | Completed | Beni-Suef University | 200 | 2023-10-15 | 2024-10-16 |
| Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension Egito, Empagliflozin + telmisartan - Hypertension Associated, Type II Diabetes Mellitus | Phase 3 | Withdrawn | EMS | 2023-08-01 | 2023-09-08 | |
| Study to Evaluate the Safety and Pharmacokinetics of CKD-379 CKD-379, D759+D745+D029+D150 - Type II Diabetes Mellitus | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 32 | 2023-06-02 | 2023-07-19 |
| Pharmacokinetics and Safety/Tolerability of CKD-379 CKD-379, D759+D745+D150 - Type II Diabetes Mellitus | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 32 | 2023-02-27 | 2023-05-11 |
| Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects CKD-371 - Type II Diabetes Mellitus | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 32 | 2022-10-21 | 2023-03-22 |
| Dual Task Performance and Type II Diabetes Mellitus one task, dual task - Type II Diabetes Mellitus, Dual Task Cost | Completed | Kahramanmaras Sutcu Imam University | 141 | 2022-09-01 | 2025-08-06 |
Showing 20 of 84. Sign in to see all of them.
Diabetes Mellitus, Type 2 (84) · Diabetes Mellitus (15) · Obesity (4) · Cardiovascular Diseases (3) · Glycosuria (3) · Hypertension (3) · Metabolic Diseases (3) · Coronary Artery Disease (2) · Dyslipidemias (2) · Glucose Metabolism Disorders (2) · Insulin Resistance (2) · Metabolic Syndrome (2) · Motor Activity (2) · Arterial Occlusive Diseases (1) · Bursitis (1)
Endocrine System Diseases (84) · Nutritional and Metabolic Diseases (84) · Glucose Metabolism Disorders (82) · Metabolic Diseases (81) · Diabetes Mellitus (69) · Cardiovascular Diseases (7) · Pathological Conditions, Signs and Symptoms (6) · Vascular Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (5) · Urogenital Diseases (5) · Body Weight (4) · Female Urogenital Diseases (4) · Heart Diseases (4) · Hyperinsulinism (4) · Male Urogenital Diseases (4)
Metformin (5) · empagliflozin (3) · AZD1656 (2) · Atorvastatin (2) · Educational Status (2) · Exercise (2) · Fenofibrate (2) · Pioglitazone (2) · Vildagliptin (2) · ipragliflozin (2) · pitavastatin (2) · 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (1) · Acarbose (1) · Diet (1) · Dorzagliatin (1)
Chong Kun Dang Pharmaceutical (8) · AstraZeneca (7) · Akros Pharma Inc. (2) · Astellas Pharma Inc (2) · EMS (2) · Getz Pharma (2) · Kowa Research Europe (2) · Merck Sharp & Dohme LLC (2) · Novartis Pharmaceuticals (2) · Riphah International University (2) · Sun Pharmaceutical Industries Limited (2) · University of Pennsylvania (2) · University of Toronto (2) · American Scitech International (1) · Aristotle University Of Thessaloniki (1)
United States (24) · South Korea (11) · Germany (9) · India (7) · Pakistan (7) · United Kingdom (6) · China (5) · Poland (5) · Taiwan (5) · Canada (4) · Denmark (3) · Latvia (3) · Netherlands (3) · Romania (3) · Russia (3)
Jaeseong Oh, M.D., Ph.D. (2) · A H Aamir (1) · Abdul Basit, Director (1) · Abdul Rahman Shahab, MPH (1) · Abhay Raut, MD (1) · Aled Roberts (1) · Allan Copland (1) · CY Wang (1) · Calum MacKenzie (1) · Christos Liapis, PhD,MD (1)
PMID 42139267, PMID 16843192, PMID 17586747, PMID 18413173, PMID 20149706, PMID 21339423, PMID 22284243, PMID 23782529, PMID 25023926, PMID 26504524, PMID 27583476, PMID 29032139, PMID 29087390, PMID 29635505, PMID 29976553, PMID 30158840, PMID 31606880, PMID 31915153, PMID 32642971, PMID 34389003, PMID 35403793, PMID 36443769, PMID 39963952, PMID 41088044, PMID 41630102, PMID 41894450, PMID 42608317
2008 (1), 2018 (1), P20HL113444 (1), P30AG034546 (1), R01DK107680 (1), R21HL113717 (1)